(Q30240229)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

review article

1 reference

title

Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

0 references

0 references

1 reference

Giuseppe Maria Milano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Giuliano Tocci

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

4

Delia Goletti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

author name string

Andrea Matucci

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Daniele Cammelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Fabrizio Cantini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Valentina Marino

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Raffaele Scarpa

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Enrico Maggi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Alessandra Vultaggio

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

language of work or name

English

0 references

publication date

1 December 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

29 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

issue

sup1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

page(s)

3-10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort

29 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Management of rheumatoid arthritis: summary of NICE guidance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Treatment of rheumatoid arthritis with biologic DMARDS (Rituximab and Etanercept)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Immunogenicity, the elephant in the room. Comment on "Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases".

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Acute infusion reactions induced by monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Hypersensitivity reactions to biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Unresolved issues in biologic therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Engineering fully human monoclonal antibodies from murine variable regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Etanercept in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Profile of certolizumab and its potential in the treatment of psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

The implications of immunogenicity for protein-based multiple sclerosis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Minimizing the immunogenicity of antibodies for clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Antidrug antibodies in psoriasis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Comparison of the NIDS® rapid assay with ELISA methods in immunogenicity testing of two biotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Adverse effects of golimumab in the treatment of rheumatologic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Certolizumab pegol for the management of Crohn's disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Certolizumab pegol in rheumatoid arthritis: current update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1221398

10.1080/14740338.2016.1221398

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27924646%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference